Register OnlineCMOD Europe Biomarkers Symposium
"DISEASE RESEARCH AND WORLDWIDE
BIOMARKER INITIATIVE"
May 1-2, 2012, Dublin Castle, Dublin, Ireland
|
|
| This program is organized in collaboration with representatives from European Medicines Agency (EMA), Health Canada, US Food and Drug Administration (FDA), the Irish Medicines Board, Molecular Medicine Ireland, University College Dublin, the Montreal Heart Institute and the Brigham and Women’s Hospital. The objective of this 2-day event is to promote innovation and efficiency in cardiovascular healthcare through the development and application of biomarkers. The program faculty, including experts from academia, industry and government, will critically examine the role of: inflammatory pathways, personalized medicine, advanced imaging, emerging sciences, new frontiers for discovery, nutrition and wellness, regulatory policy, safety biomarker initiatives, global harmonization, and data mining and integration in the advancement of biomarkers-supported healthcare. The meeting will be held at Dublin Castle. |
For more information, please contact Therese Heinonen at therese.heinonen@mhicc.org
Recent Events
 9TH Annual CMOD United States
Biomarkers Symposium
September 12-13, 2011, FDA Campus
10903 New Hampshire Ave, White Oak, Maryland, USA
|
 
|
|
Thank you to everyone who contributed to the success of 9th annual CMOD US symposium. The meeting was held in collaboration with representatives from the National Institutes of Health (NIH) and the US Food and Drug Administration (FDA). This educational program addressed biomarker development, qualification, and application in cardiology, nephrology, and oncology. The expert CMOD faculty members presented cutting edge research initiatives and findings on the biomarkers, emerging sciences, and imaging technologies which are rapidly shaping medical practice. Over 180 attendees including more that 140 colleagues from various divisions of FDA participated. |
 3rd Annual CMOD Canadian Biomarkers
and Surrogate Endpoints Meeting
"BIOMARKERS AND EMERGING SCIENCES"
May 24-25, 2011, Ottawa, Ontario, CANADA |
|
| This program was co-sponsored by Health Canada and Canadian Institutes of
Health Research (CIHR). The program provided colleagues with the opportunity to learn
of clinical challenges in cardiovascular disease, diabetes,
neurovascular/degenerative disease, and cancer that may be addressed with
the development of biomarkers and emerging sciences such as genomics,
proteomics, and imaging technologies. Particular emphasis was placed
on the role of personalized medicine in the advancement of healthcare,
including global challenges and solutions. This program included a
number of case studies from industry and academic leaders in the field, and
addressed advancing regulatory sciences and policy in the face of emerging
technologies and challenges. |
|
about us